Here is what the page “STAT+: Novo Nordisk’s next-gen obesity drug stumbles in comparison study | Nova Global New” contains. Novo Nordisk's next-generation obesity drug CagriSema underperformed versus Eli Lilly's Zepbound in a head-to-head study. Nova Global News curates publicly available headlines and summaries with source attribution. Third-party article rights, trademarks, images, and publisher names belong to their respective owners;
read the original article at the source for full context. Part of the Nova Ecosystem — the platform where AI apps, news, and tools are built and deployed. [ LIVE 🧠 Nova Ecosystem PLATFORM Our Platform Nova AI MetaBrain 84 AI Assistants — Videos, images, code & more. For the complete material, the listing points back to the source inside the network.